Status:
TERMINATED
Alster Stem Cells - Intramyocardial Stem Therapy
Lead Sponsor:
Asklepios proresearch
Conditions:
Acute Myocardial Infarction
Early Left Ventricular Dysfunction
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Study to assess the efficacy of intramyocardial bone marrow derived mononuclear cell therapy concerning left ventricular ejection fraction as measured by echocardiography.
Eligibility Criteria
Inclusion
- LVDF \< 45% after timely (max. 6 hours after the onset of symptomps) successful PCI
- conventional therapy according to the ESC guidelines for heart failure
- BMI \> 20 and \< 35
Exclusion
- PCI elder then 21 days
- relevant valvular disease
- history of stroke/multivessel disease/thromboembolic event etc.
- DM Type I
- pregancy
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00939042
Start Date
January 1 2009
End Date
January 1 2014
Last Update
October 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asklepios Klinik St. Georg
Hamburg, Germany